Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...

New strategies promise to streamline workflows, conserve consumables, increase productivity, and enhance reproducibility.

State Key Laboratory of Organic−Inorganic Composites, Beijing Key Laboratory of Bioprocess, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and ...

Starlink has increased the Standard kit price from $350 to now $389 in Zimbabwe and other countries in Africa. The price for the Mini kit remains at $200 and is still available to order ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, linking its hereditary angioedema (HAE) prospect to an 81% reduction in ...

NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 targets the gene encoding ...

The therapy, dubbed NTLA-2002, is based on the CRISPR gene editing technology that won a Nobel Prize in 2020. The treatment is designed to inactivate a gene involved in potentially life-threatening ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...